✦ LIBER ✦

Efficacy of low-dose imatinib in chronic-phase chronic myelogenous leukemia patients

✍ Scribed by S. Kobayashi; F. Kimura; A. Kobayashi; K. Sato; K. Motoyoshi

Book ID: 105989259
Publisher: Springer
Year: 2008
Tongue: English
Weight: 41 KB
Volume: 88
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-008-0612-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of imatinib dose escalation in

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

✍ Hagop M. Kantarjian; Richard A. Larson; Francois Guilhot; Stephen G. O'Brien; Ma 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 230 KB 👁 3 views

Erratum: Efficacy of imatinib dose escal

Erratum: Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

✍ Hagop M. Kantarjian; Richard A. Larson; Francois Guilhot; Stephen G. O'Brien; Ma 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB 👁 2 views

Persistent neutropenia in chronic myelog

Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

✍ Yu-Yan Hwang; Eric Tse; Jason C.C. So; Thomas S.K. Wan; Yok-Lam Kwong 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB 👁 1 views

A physician or a group of physicians considers presentation and evolution of a real clinical case, reacting to clinical information and data (boldface type). This is followed by a discussion/commentary.

Phase 1 study of tipifarnib in combinati

Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure

✍ Jorge Cortes; Alfonso Quintás-Cardama; Guillermo Garcia-Manero; Susan O'Brien; D 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 2 views

## Abstract ## BACKGROUND. The tolerability and efficacy of the combination of tipifarnib, an orally bioavailable nonpeptidomimetic farnesyl transferase inhibitor, and imatinib was investigated in patients with chronic myelogenous leukemia in chronic phase who had failed imatinib. ## METHODS. Tw

Significance of myelofibrosis in early c

Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy

✍ Hagop M. Kantarjian; Carlos E. Bueso-Ramos; Moshe Talpaz; Susan O'Brien; Francis 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB 👁 2 views

## Abstract ## BACKGROUND Myelofibrosis is associated historically with a poor prognosis in patients with chronic myelogenous leukemia (CML). Its significance in the recent era of effective therapy with imatinib mesylate is unknown. ## METHODS The current study evaluated the significance of the

The significance of myelosuppression dur

The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase

✍ Thomas B. Sneed; Hagop M. Kantarjian; Moshe Talpaz; Susan O'Brien; Mary Beth Rio 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 1 views

## Abstract ## BACKGROUND Imatinib mesylate induces high rates of hematologic and cytogenetic response in patients with chronic myelogenous leukemia (CML). During therapy with imatinib, up to 45% of patients with CML reportedly experience myelosuppression ≥ Grade 3, requiring interruption of thera